A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Study Overview
=================
Brief Summary
-----------------
To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.

Detailed Description
-----------------
To establish the efficacy of a 20 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa. Patients who meet entry criteria will be randomized in a 1 to 1 ratio to either istradefylline or matching placebo. Patients will be treated for 12 weeks and will have interim visits and end of treatment visit to assess the efficacy and safety of istradefylline as compared to placebo.

Official Title
-----------------
A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: Istradefylline (KW-6002)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: UK Parkinson's Disease Society (UKPDS) brain bank criteria (Step 1 and 2) for PD. PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale. On levodopa/carbidopa for at least one year, stable dose in past 4 weeks. Currently take at least three doses of levodopa/carbidopa per day. Predictable end of dose wearing off. Able to satisfactorily complete Hauser version of a Parkinson's diary. Have an average of 180 minutes of OFF time on two 24 hour diaries. Be at least 30 years of age. Exclusion Criteria: Neurosurgical treatment for PD. History of psychosis. Diagnosis of atypical parkinsonism, secondary parkinsonism variant or Parkinson's plus syndromes. Diagnosis of cancer within 5 years. Mini-mental status examination score of 25 or less. History of seizures or neurologic malignant_syndrome. Clinical depression.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Istradefylline (KW-6002)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To establish the efficacy of a 20 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of a 20 mg/d dose of istradefylline for reducing the total hours of OFF time. |  |  | 
| To evaluate the change in percentage of ON time (without dyskinesia, with dyskinesia, with non-troublesome dyskinesia, and with troublesome dyskinesia). |  |  | 
| To evaluate the change in Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination score (part III) and/or in Activities of Daily Living (ADL) score (part II). |  |  | 
| To evaluate the change in Parkinson's Disease Questionnaire (PDQ-39) and Medical Outcomes Study 36-item Short Form (SF-36). |  |  | 
| To evaluate the change in the Patient Global Impression - Improvement scale (PGI-I). |  |  | 
| To evaluate change in the Clinical Global Impression - Severity of Illness scale (CGI-S). |  |  | 
| To evaluate the safety of a 20 mg/d dose of istradefylline. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, levodopa, end of dose wearing off, OFF time